Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and nine month periods ended December 31, 2012.
Quarter ended December 31, 2012 Highlights - compared to December 31, 2011
• Net sales of $185.7 million, increased $37.6 million, or 25.4%, however, sales volumes have slightly declined
• Gross profit, as a percentage of net sales was 75.4%, compared to 71.6%
